Appointment dossier — Endometrial Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Endometrial Cancer
- Pembrolizumab — Human evidence · 2 positive / 1 negative-mixed · PMID 38422895, 34210768, 36874745, 31074865
- Atezolizumab — Human evidence · 1 positive · PMID 38422895
- Avelumab — Human evidence · 1 positive · PMID 38422895
- Dostarlimab — Human evidence · 1 positive · PMID 38422895
- Durvalumab — Human evidence · 1 positive / 1 negative-mixed · PMID 38422895, 36512912
- Carboplatin — Review evidence · 1 positive / 1 negative-mixed · PMID 24328598, 33183764
- Lenvatinib — Review evidence · 1 positive · PMID 34210768, 36874745
- Paclitaxel — Review evidence · 1 positive · PMID 24328598
- Tamoxifen — Review evidence · 0 positive / 1 negative-mixed · PMID 32906618
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06584032 · Phase 3 — Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer (China)
- NCT07198074 · Phase 3 — Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (United States)
- NCT07319429 · Phase 2 / Phase 3 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (China)
- NCT07341737 · Phase 1 / Phase 2 — SL-28 for Advanced Solid Tumours (Australia)
- NCT04657068 · Phase 1 / Phase 2 — A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (United States)
- NCT06073184 · Phase 2 — Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium (Canada)
- NCT05795244 · Phase 2 — Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) (South Korea)
- NCT06547840 · Phase 1 — A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha (United Kingdom)
- NCT06603506 — Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study (France)
- NCT06360653 — a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer (Italy)
- NCT04997096 — Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy (United States)
- NCT06893861 — Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer (Italy)
- NCT05349227 — Comprehensive Outcomes for After Cancer Health (United States)
- NCT07200466 — Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation (Netherlands)
- NCT07220239 — Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome (United States)
- NCT04453904 — Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer (China)
- NCT06447064 — Cancer Loyalty Card Study 2 (CLOCS-2) (United Kingdom)
- NCT02012699 — Integrated Cancer Repository for Cancer Research (United States)
Most-relevant first: trials that name Endometrial Cancer, then broader trials you may still qualify for. 345 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Pembrolizumab has been studied in people for Endometrial Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that Atezolizumab has been studied in people for Endometrial Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that Avelumab has been studied in people for Endometrial Cancer — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT06584032), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?